Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...

In a case with implications for the litigious molecular diagnostics space and written description law, Chief Judge Connolly of the District of Delaware reversed a $96 million jury verdict in favor of ...

Scientists have tapped into the Summit supercomputer to study an elaborate molecular pathway called nucleotide excision ...

The Vietnam Hepatitis Treatment Market was valued at USD 146.25 million in 2023 and is projected to reach USD 197.35 million by 2029, growing at a CAGR of 5.08% during the forecast period. The ...

Imagine a world where we could predict the behavior of life just by analyzing a sequence of letters. This is not science ...

Researchers at Georgia State University used the Summit supercomputer to study an elaborate molecular pathway called ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...

Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a ...